(Q87550003)
Statements
Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors (English)
Jeffrey R Infante
Anthony J Olszanski
Shyeilla V Dhuria
Suman Sen
Scott Cameron